Almost everywhere, spine belongs to the multinationals. Brazil doesn’t follow the script, and the reasons run deeper than price.
Run down the top of the spine market in the US, Europe or most of Asia and the same names keep showing up: Medtronic, DePuy Synthes, Stryker (VB Spine) , Globus Medical. Brazil is the odd one out. The biggest slice of the market there belongs to domestic companies most people in this industry couldn’t name, built around the orthopedic clusters of interior São Paulo rather than Memphis.
The tempting read is that Brazil simply hasn’t caught up. It has. The local lead isn’t a gap waiting for better imported technology to close it. It’s baked into how the country’s health system, its regulator, its tax code and its distribution channel actually work. Get those right and you understand why so many global manufacturers have spent years in Brazil without ever really cracking it.
A quick word on size, because the reports don’t agree and you should know that before you quote one. iData Research put the spinal implant and VCF market near US$410 million in 2023, growing about 6% a year. Grand View landed a little higher. The bullish forecasts reach US$850 million by 2033. Call it somewhere above US$410 million today, compounding in the mid-to-high single digits, and you’re on safe ground. Either way, Brazil is the largest spine market in Latin America, the population is aging, and minimally invasive surgery is the piece growing fastest. Hold that last point. It matters at the end.
Two systems, two markets
Start with the thing that explains the most. Brazil runs two health systems at once, and they buy implants in opposite ways. The public SUS covers essentially everyone, around 220 million people, free at the point of care, and it purchases through procurement: lowest qualified bid, big volumes, constant pressure on price. Private supplementary plans cover roughly a quarter of the population, about 52 million lives, and that is where the money per case sits.
So the volume lives in the system that buys on price, and the premium lives in the smaller one. A foreign maker can own the high end and still lose the share war. That is more or less what the numbers say: iData had ZimVie leading the multinationals in 2023, DePuy next, and the locals still ahead in aggregate.
A regulator and a cost base that point the same way
Then there is ANVISA, which foreign teams tend to file under “compliance” when they should be filing it under “competitive moat.” Registration under RDC 751/2022 is slow and expensive, and an importer carries customs risk and the standing threat of a shipment stuck at the border on top of it. A company that makes and registers its product at home doesn’t live with that fragility. Add procurement rules that can favor domestically produced goods, and the regulator quietly hands the local player an edge it never has to defend.
Cost finishes the job. Import duties, a heavy tax load and a jumpy currency pile onto anything that crosses the border, and in a market that buys much of its volume on price, that is the difference between winning a tender and losing it. The locals aren’t cheap because they cut corners, either. Many grew out of Rio Claro, a real metalworking and orthopedic hub, and they know how to make things well.
The channel decides the case
Distribution is where the whole thing gets settled. Spine in Brazil moves through distributors and consignment, and the deal happens inside the triangle of distributor, surgeon and hospital. Device choice sits close to the surgeon and has always been relationship-driven, which is why OPME, the category covering orthoses, prostheses and special materials, has drawn steady regulatory attention and a long run of cost-control measures, from a national implant registry to a continuing push for pricing transparency.
For anyone trying to break in, the lesson holds whatever the policy weather: the channel, not the catalog, controls the case. Those relationships are an asset a multinational can’t buy with a nicer cage, and they are held, overwhelmingly, by companies that have been inside the system for decades.
The locals
None of this makes the locals garage operations. GMReis, founded in 1989 by a Unicamp engineer, was in spine by 1995 and now exports, with Pátria Investimentos behind it, which tells you private equity sees a national champion worth building. Baumer has been at this since 1952 and carries certifications across three continents. Traumec came out of the Rio Claro cluster in 2007 and already holds dozens of ANVISA registrations. Behind them is a crowded field, from Ortosíntese to Neoortho to Sartori.
- Baumer
- Biomecanica Group
- GMReis
- Víncula
- Neoortho
- Óssea Medical Technology
- OSTEOMED Implantes
- Ortosintese
- SARTORI
- Spinestahl
- TRAUMEC
Where I’d push on my own argument
Volume, cost and channel favor the locals. The frontier does not. MIS, navigation, robotics, motion preservation, the better biologics: that is multinational ground, and as Brazilian surgery grows more complex (there is that 10% MIS growth again) the premium pool expands into exactly the space the global names defend best.
So the real race is whether GMReis and the rest can climb up-market before the multinationals can get their costs down. The money behind GMReis is a bet that they can. And every step toward transparency, from the registry to value-based purchasing, chips away at the distribution moat, which would help the foreigners more than anyone.
For now, Brazil rewards whoever is already inside the gate, and that is the local manufacturer. Not because their implants are better. Because the market is built that way, and a better implant was never going to be the thing that changed it.
###
Legal Disclaimer:
Content published on SPINEMarketGroup (thespinemarketgroup.com) is provided for informational purposes only and on an “as is” basis, without warranties of any kind. We do not guarantee the accuracy, completeness, legality, or reliability of any information, images, videos, links, or third-party materials featured on the site. Any views or claims expressed in contributed content or press releases belong to their respective authors or sources. For copyright concerns, factual corrections, or content-related complaints, please contact us directly for review.